---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010114"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T16:57:25.231673+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics enters amended CEO agreement with $300K salary, transaction bonus provision

## Summary
- CEO Jeffrey Frelick receives $300,000 annual base salary, bonus target of 50% of salary, and transaction bonus of 1-2% of deal value upon acquisition.
- CFO Deina Walsh granted transaction bonus eligibility of 0.5-1% of deal value via amendment effective March 11, 2024.
- Frelick's agreement renews automatically; severance includes one year base salary plus COBRA coverage for one year if terminated without cause.
- Both agreements contain standard restrictive covenants and will be filed in the next quarterly report.

## SEC filing metadata
- accession: 0001493152-24-010114
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315224010114/0001493152-24-010114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315224010114/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010114
- JSON: https://secwatch.observer/filing/0001493152-24-010114.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.